pharmaceutical investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical investing Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
pharmaceutical investing Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
Standard Uranium Retains 100% Unencumbered Ownership of the Sun Dog Project Through Conclusion of Property Option Agreement
RZOLV Technologies Appoints Mary Ellen Thorburn to the Board of Directors; Announces the Retirement of Darryl Yea
